Clinical Trial Update: Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating Livoletide (AZP-531) for food-related behaviors in Prader-Willi Syndrome was terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperphagia
• Prader-willi Syndrome

Drugs mentioned

• Livoletide (AZP-531)

Snippet

Sponsor: Millendo Therapeutics SAS | Conditions: Prader-Willi Syndrome, Hyperphagia | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2021-02-17